Author
Listed:
- Zoraida Verde
(Department of Biochemistry, Molecular Biology and Physiology, Universidad de Valladolid, Campus Duques de Soria, 42004 Soria, Spain)
- Laura García de Diego
(Department of Nursery, Universidad de Valladolid, Campus Duques de Soria, 42004 Soria, Spain)
- Luis M. Chicharro
(Cátedra Complutense Diagnostic and Innovation, Universidad Complutense, 28040 Madrid, Spain)
- Fernando Bandrés
(Cátedra Complutense Diagnostic and Innovation, Universidad Complutense, 28040 Madrid, Spain
Department of Toxicology and Health Sanitary, Universidad Complutense, 28040 Madrid, Spain)
- Verónica Velasco
(Department of Nursery, Universidad de Valladolid, 47005 Valladolid, Spain)
- Teresa Mingo
(Department of Surgery, Ophthalmology, Otorhinolaryngology and Physiotherapy, Universidad de Valladolid, Campus Duques de Soria, 42004 Soria, Spain)
- Ana Fernández-Araque
(Department of Nursery, Universidad de Valladolid, Campus Duques de Soria, 42004 Soria, Spain)
Abstract
Older adults are at increased risk of several cytochrome P450 (CYP) drug interactions that can result in drug toxicity, reduced pharmacological effect, and adverse drug reactions. This study aimed to assess the prevalence of potential CYP interactions referring to the most clinically relevant drugs and exploring the relationship between them and quality of life and physical performance in Spanish octogenarians. Institutionalized and community-dwelling octogenarians ( n = 102) treated at three primary care centers, were recruited by a research nurse. Anthropometric measurements, chronic diseases, prescribed drugs, quality of life, physical performance, mobility skills, hand grip strength and cognitive status data were collected. Potential CYP drug-drug interactions (DDIs) were selected referring to the main CYP implicated in their metabolism. The 72.2% of recruited octogenarians presented potentially inappropriate CYP inhibitor-substrate or CYP inductor-substrate combinations. Analyzing the EuroQol Visual Analogue scale (EQ-VAS) results, patients with a potential CYP DDI perceived worse health status than patients without it ( p = 0.004). In addition, patients with a potential CYP DDI presented worse exercise capacity, kinesthetic abilities, or mobility than those who didn’t present a potential interaction ( p = 0.01, p = 0.047, and p = 0.02, respectively). To investigate and control factors associated with loss of muscle strength and poor quality of life, polypharmacy and DDIs could help institutions in the management of physical frailty.
Suggested Citation
Zoraida Verde & Laura García de Diego & Luis M. Chicharro & Fernando Bandrés & Verónica Velasco & Teresa Mingo & Ana Fernández-Araque, 2019.
"Physical Performance and Quality of Life in Older Adults: Is There Any Association between Them and Potential Drug Interactions in Polymedicated Octogenarians?,"
IJERPH, MDPI, vol. 16(21), pages 1-10, October.
Handle:
RePEc:gam:jijerp:v:16:y:2019:i:21:p:4190-:d:281547
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:16:y:2019:i:21:p:4190-:d:281547. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.